Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
Can a new drug combo help men with advanced prostate cancer?
In a single-arm phase 1b/2 trial of 37 patients with mCRPC, Lu-PSMA-617 plus pembrolizumab achieved a 50% PSA decline in 28 participants (76…
A new drug combo helped 28 of 37 men with advanced prostate cancer cut their PSA levels in half while keeping side effects mostly mild to mo…
Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
Can a drug help keep lung cancer from returning after surgery?
A Phase 3 randomized controlled trial in 1177 participants with resected Stage IB-IIIA NSCLC compared adjuvant pembrolizumab to placebo. The…
A large trial tested whether the drug pembrolizumab helps keep early-stage lung cancer from returning after surgery for over 1,100 patients.
Phase 2 trial links early monocyte elevation to response in gastric cancer immunotherapy
Small study finds immune cell changes linked to better response in gastric cancer treatment
A phase 2 trial in 24 patients with metastatic gastric cancer receiving first-line pembrolizumab plus XELOX found that early elevation of ci…
Patients with metastatic gastric cancer who saw early immune cell changes in their blood were more likely to survive longer while receiving …
Phase 3 trial of pembrolizumab plus chemo for advanced biliary tract carcinoma posts results
Can adding pembrolizumab to standard chemo help people with advanced bile duct cancer?
A phase 3 randomized controlled trial in 1,069 participants with advanced biliary tract carcinoma compared first-line pembrolizumab plus gem…
A large trial of adding immunotherapy to standard chemo for advanced bile duct cancer is complete, but the results showing if patients live …
Pembrolizumab ranks highest for survival in cervical cancer network meta-analysis
Review finds pembrolizumab may improve survival in advanced cervical cancer
A Bayesian network meta-analysis of phase 3 RCTs compared immune checkpoint inhibitors in locally advanced and metastatic cervical cancer. P…
Adding pembrolizumab to standard treatment for advanced cervical cancer is linked to better survival and longer time before the disease prog…
Meta-analysis: PD-1/PD-L1 inhibitors show 45% ORR, 16.27-month median OS in recurrent/metastatic NPC
For advanced nasopharyngeal cancer, can immune therapy help? New analysis shows what patients might expect.
A meta-analysis of 9 studies (883 patients) found PD-1/PD-L1 inhibitors for recurrent/metastatic nasopharyngeal carcinoma yielded a median O…
For advanced nasopharyngeal cancer, immune therapy helps 43% stay cancer-free for a year while 80% survive, though side effects affect 90% o…
PD-1 inhibitors + chemo improve OS, PFS, ORR in first-line advanced ESCC; benefit limited in PD-L1 CPS <1
Who benefits most from new esophageal cancer treatment? Most patients do, except one group.
A meta-analysis of 8 RCTs (n=4702) found first-line PD-1 inhibitors plus chemotherapy significantly improved OS (HR=0.68, 95% CI: 0.63-0.74;…
For most advanced esophageal cancer patients, adding immunotherapy to chemotherapy extends life and shrinks tumors, but those with low PD-L1…
Phase 2 trial of neoadjuvant/adjuvant pembrolizumab in stage IB-IIIA NSCLC completes enrollment of 35 patients
Can immunotherapy before lung cancer surgery help the immune system fight the tumor?
A multi-institutional phase 2 trial has completed enrollment of 35 patients to study neoadjuvant and adjuvant pembrolizumab in stage IB, II,…
Doctors tested giving immunotherapy before lung cancer surgery to see if it safely boosts the immune system's ability to fight the tumor.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanoma
Can a new drug help people with a rare eye cancer live longer?
This Phase II study evaluated IMCgp100 versus investigator's choice (dacarbazine, ipilimumab, or pembrolizumab) in HLA-A*0201 positive adult…
A new drug for advanced eye cancer is being compared to standard treatments to see if it helps patients with a specific genetic marker live …
Phase 3 trial compares pembrolizumab with or without lenvatinib in PD-L1+ recurrent/metastatic HNSCC
Phase 3 trial tests pembrolizumab with or without lenvatinib for advanced head and neck cancer
A phase 3 randomized controlled trial enrolled 511 patients with PD-L1 selected recurrent or metastatic head and neck squamous cell carcinom…
A completed Phase 3 trial tested pembrolizumab with or without lenvatinib for advanced head and neck cancer, but detailed results are not ye…
Phase III trial tests TTFields plus standard therapy for stage 4 NSCLC after platinum failure
Can adding electric fields to standard treatment help people with advanced lung cancer?
A prospective, randomized phase III trial in 291 patients with stage 4 NSCLC after platinum progression compared TTFields plus standard ther…
Doctors are testing if adding a wearable electric field device to standard drugs helps people with advanced lung cancer live longer after ch…
Low sADC Predicts Poor Outcomes in Cervical Cancer with PD-1 Inhibitors
Can imaging predict how well cervical cancer patients respond to treatment?
In a study of 167 cervical cancer patients, lower substantial ADC (sADC) correlated with worse PFS (HR=1.81, P=0.005) and OS (HR=2.40, P=0.0…
Low water movement in cervical cancer tumors on scans predicts worse survival when patients take immunotherapy, helping doctors choose bette…